UBS Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and set a price target of $35.
October 24, 2024 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on Nurix Therapeutics with a Buy rating and a price target of $35, indicating a positive outlook for the stock.
The initiation of coverage by UBS with a Buy rating and a specific price target of $35 suggests a positive sentiment from a reputable financial institution. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100